This 10-Strain Yogurt Relieved Constipation, Anxiety, and Poor Sleep in a Clinical Trial

A specialized fermented yogurt containing ten distinct probiotic strains appears to do something ordinary yogurt cannot: not only relieve chronic constipation, but also reduce anxiety and improve sleep quality, all within four weeks. Researchers behind a new randomized controlled trial published in the Journal of Functional Foods trace those benefits to a single microbial thread, the enrichment of Bacteroides species and the short-chain fatty acids they produce.

K-10 Yogurt Reduces Constipation Scores Below the Clinical Threshold

The product at the center of the trial is called K-10, a multi-strain yogurt developed from indigenous lactic acid bacterial strains collected in Inner Mongolia and Tibet. Its ten-strain formula, now covered by a Chinese patent, includes familiar species like Lactobacillus acidophilus, L. rhamnosus, and Bifidobacterium lactis alongside less common fermenters such as Leuconostoc mesenteroides and Lactococcus lactis subspecies. Each gram contains between 10 billion and 500 billion viable bacteria.

The double-blind trial enrolled 220 adults aged 20 to 50 with functional constipation diagnosed under Rome IV criteria. After 9.5% attrition, 199 participants completed the four-week intervention. Those in the K-10 group saw their Cleveland Clinic Constipation Scores (CCS) fall below 15, the recognized clinical threshold for significant constipation, a shift that was statistically significant at P < 0.001. Specifically, K-10 improved all five core constipation symptoms measured: bowel movement frequency increased, straining decreased, the sensation of incomplete evacuation eased, toileting time shortened, and the number of unsuccessful defecation attempts dropped.

The control arm received regular commercial yogurt, and the contrast was stark: participants in that group actually saw a reduction in beneficial Bacteroides species and an increase in Pseudomonas, a genus associated with pathogenic potential.

Why Constipation, Anxiety, and Poor Sleep So Often Travel Together

Chronic constipation affects roughly 14% of adults globally, but the burden rarely stops at the gut. Research on constipation and anxiety comorbidity has found anxiety prevalence as high as 41.4% among people with constipation, compared to 26.0% in those without it. Separately, patients with functional constipation who experience poor sleep tend to report worse gastrointestinal symptoms, suggesting the relationship runs in both directions.

The K-10 trial took this clustering seriously and measured all three domains simultaneously. On the Generalized Anxiety Disorder-7 scale, fewer K-10 participants experienced moderate-to-severe anxiety after the intervention. On the Pittsburgh Sleep Quality Index, K-10 specifically improved sleep latency and reduced dependence on hypnotic medication, both reaching P < 0.05. Regular yogurt produced no comparable shifts on either scale.

The gut-brain axis is the likely conduit. K-10 increased serum serotonin (5-HT) levels significantly more than regular yogurt (P < 0.001), and it was the only intervention to raise dopamine levels (P < 0.001). Both neurotransmitters are synthesized in part by gut microbes and are well-established regulators of mood and sleep. Cortisol and melatonin levels were also measured, giving the team a more complete neurochemical picture than most probiotic trials attempt.

How a Double-Blind Design Strengthens These Results

Double-blind, placebo-controlled randomized controlled trials are considered the gold standard for human gut microbiota intervention studies, and the K-10 researchers used an active control rather than a placebo, which raises the bar further: participants in the control arm consumed real yogurt with live cultures, meaning any advantage K-10 showed cannot be attributed simply to eating fermented food.

To probe the mechanism, the team sequenced gut microbiota via 16S ribosomal RNA gene analysis and measured fecal short-chain fatty acids (SCFAs) by gas chromatography-mass spectrometry. K-10 significantly increased acetic acid and butyric acid concentrations. One species in particular, Bacteroides uniformis, showed strong positive correlations with both acetate and butyrate (P < 0.01) and significant negative correlations with CCS score, sleep quality score, and TNF-α levels. The researchers named this relationship the "Bacteroides-SCFAs Axis."

Inflammatory markers fell too: TNF-α dropped by 34.2% and IL-6 by 39.8% in the K-10 group (both P < 0.05). Antioxidant status improved, reflected in higher superoxide dismutase activity and total antioxidant capacity. KEGG pathway analysis showed K-10 enriched enzymes involved in polysaccharide degradation, which would help explain the elevated SCFA output.

Open Questions About Trial Length, Sex Balance, and Sequencing Depth

The four-week window is the study's most obvious constraint. Benefits persisted for at least two weeks after participants stopped taking K-10, suggesting some durability, but one participant in the K-10 group experienced an anxiety rebound two weeks after stopping, and the authors acknowledge that this isolated incident is not well explained. Longer follow-up is needed to know whether the microbiome shifts are sustained or whether symptoms creep back.

The participant pool skewed heavily female, which is common in constipation research but limits how broadly the findings apply to men. Daily diet and lifestyle were not tightly monitored, leaving room for confounders. And while 16S sequencing reliably identifies which bacteria are present, it does not confirm what those bacteria are doing functionally: the KEGG pathway inferences need validation through metagenomics or metabolomics in future work. These are not fatal flaws, but they are the kinds of methodological gaps that make standardized microbiome diagnostics difficult to translate into clinical settings.

What a Bacteroides-Targeted Probiotic Could Mean for Gut-Brain Medicine

If the Bacteroides-SCFAs mechanism holds up in larger, longer trials, K-10 or a similar multi-strain product could become one of several gut microbiome therapeutic strategies for psychological disorders that are now moving from concept into clinical testing. The current trial is a solid proof-of-concept: it used validated clinical scales for three separate conditions, measured relevant biomarkers, and showed statistically significant improvements across all of them.

The strain diversity in K-10 is probably not accidental. The authors sourced bacteria from two regions known for traditional fermented dairy, Inner Mongolia and Tibet, a sourcing decision that may have selected for strains with strong Bacteroides-supporting properties. Whether that geographical origin is essential or merely convenient is an interesting question for formulators. For now, the data suggest that not all yogurts are created equal, and that the specific strains inside the cup may matter far more than the yogurt category as a whole.

Evidence rating

EMERGING — 84/100

Caveats:

• Single 4-week RCT — long-term durability of effects is unknown, and one participant experienced anxiety rebound after stopping K-10.
• Participants were predominantly female (aged 20–50), limiting generalizability to male or older populations.
• Daily diet and lifestyle were not strictly controlled, introducing potential confounding.
• Gut microbiota changes are associative, not causally proven — functional pathways were inferred from 16S rRNA sequencing and require validation by metagenomics or metabolomics.
• The K-10 probiotic blend is covered by a Chinese patent; independent replication with the same formulation has not yet been published.
• Funding source was not disclosed by the authors.

Double-blind, active-controlled RCT (n=199) comparing a 10-strain fermented yogurt (K-10) to conventional yogurt over 4 weeks in adults with Rome IV-diagnosed functional constipation. The study demonstrates statistically significant associations between K-10 consumption, Bacteroides enrichment, elevated short-chain fatty acids, and improvements in constipation, anxiety, and select sleep measures, but cannot establish causation due to the correlational nature of microbiome-outcome analyses and the absence of dietary controls. Results have not yet been independently replicated, and the predominantly female sample limits broader generalizability.